Alaunos Therapeutics
Open
$2.03
Prev. Close
$2.03
High
$2.03
Low
$2.01
Market Snapshot
$5.37M
-1.3
-2.92
$8K
1
Alaunos Therapeutics, Inc. is a biopharmaceutical company and clinical-stage oncology-focused cell therapy company, which engages in the development of adoptive TCR engineered T-cell therapies, or TCR-T, designed to treat multiple solid tumor types in large cancer patient populations with unmet clinical needs. The company is headquartered in Fort Lauderdale, Florida and currently employs 1 full-time employees. The company went IPO on 2004-08-20. The firm focuses on developing small molecules that are expected to be efficacious against obesity and other metabolic disorders. The firm is engaged in developing novel small molecule-based obesity therapeutics. The Company’s operations consist primarily of conducting research and development and raising capital to fund those efforts. The firm has not generated any revenues.
Alaunos Therapeutics, Inc. is a biopharmaceutical company and clinical-stage oncology-focused cell therapy company, which engages in the development of adoptive TCR engineered T-cell therapies, or TCR-T, designed to treat multiple solid tumor types in large cancer patient populations with unmet clinical needs. The company is headquartered in Fort Lauderdale, Florida and currently employs 1 full-time employees. The company went IPO on 2004-08-20. The firm focuses on developing small molecules that are expected to be efficacious against obesity and other metabolic disorders. The firm is engaged in developing novel small molecule-based obesity therapeutics. The Company’s operations consist primarily of conducting research and development and raising capital to fund those efforts. The firm has not generated any revenues.
Recently from Cashu
Alaunos Therapeutics Faces Investor Skepticism Despite Promising ALN1003 Preclinical Data
Alaunos Therapeutics: Navigating Challenges in Cancer Treatment Innovation In recent developments, Alaunos Therapeutics Inc. shares a glimpse of promise in cancer treatment research with its lead drug…
Alaunos Therapeutics Faces Investor Skepticism Despite Promising ALN1003 Preclinical Data
### Promising Advances Amid Investor Skepticism for Alaunos Therapeutics Alaunos Therapeutics Inc. is currently poised at a pivotal junction in its development of innovative cancer therapies, driven b…
Alaunos Therapeutics Faces Investor Hesitation Despite Promising ALN1003 Preclinical Data
Alaunos Therapeutics Faces Market Caution Despite ALN1003's Promising Data Alaunos Therapeutics Inc. is in a pivotal moment following the recent announcement of preclinical proof-of-concept data for i…
Please provide the content you would like me to summarize.
Sure! Please provide the text you would like me to summarize.